Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

BACKGROUND AND OBJECTIVES: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Alexandra, Dugast, Emilie, Shah, Sita, Morille, Jérémy, Lebrun-Frenay, Christine, Thouvenot, Eric, De Sèze, Jérôme, Le Page, Emmanuelle, Vukusic, Sandra, Maurousset, Aude, Berger, Eric, Casez, Olivier, Labauge, Pierre, Ruet, Aurélie, Raposo, Catarina, Bakdache, Fabien, Buffels, Régine, Le Frère, Fabienne, Nicot, Arnaud, Wiertlewski, Sandrine, Gourraud, Pierre-Antoine, Berthelot, Laureline, Laplaud, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944617/
https://www.ncbi.nlm.nih.gov/pubmed/36810163
http://dx.doi.org/10.1212/NXI.0000000000200091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944617/
https://www.ncbi.nlm.nih.gov/pubmed/36810163
http://dx.doi.org/10.1212/NXI.0000000000200091

Ejemplares similares